drug development – Page 2

Past, present and future of antifungals: Advancements in mechanisms of action and resistance

mycolabadmin

Fungal infections are a growing global health threat, especially for people with weakened immune systems, causing millions of deaths annually. Currently available antifungal drugs are limited and increasingly face resistance, making them less effective over time. This special collection of research papers explores new approaches to treating fungal infections, including novel drugs, combination therapies, and alternative treatments to overcome resistance. Scientists and doctors hope these advances will help save more lives by providing better options for treating serious fungal diseases.

Targeting SARS-CoV-2 with Chaga mushroom: An in silico study toward developing a natural antiviral compound

mycolabadmin

This study used computer modeling to investigate whether Chaga mushroom components can bind to and potentially block the coronavirus spike protein that SARS-CoV-2 uses to infect cells. The researchers found that three active compounds in Chaga—beta glycan, betulinic acid, and galactomannan—attached strongly to the virus’s binding sites in ways similar to known antiviral molecules. Beyond blocking viral entry, Chaga also has immune-boosting and anti-inflammatory properties that could help prevent the dangerous cytokine storm associated with severe COVID-19.

Antifungal Effects of the Phloroglucinol Derivative DPPG Against Pathogenic Aspergillus fumigatus

mycolabadmin

Scientists developed a new antifungal compound called DPPG based on a natural antibacterial molecule produced by soil bacteria. This synthetic derivative showed strong activity against dangerous fungal pathogens like Aspergillus fumigatus and Candida species, which cause serious infections in humans. The compound works by disrupting the fungal cell membrane, causing it to leak and die. Testing in insect models demonstrated effectiveness comparable to current clinical antifungal medications.

Sandalwood Sesquiterpene (Z)-α-Santalol Exhibits In Vivo Efficacy Against Madurella mycetomatis in Galleria mellonella Larvae

mycolabadmin

Researchers tested sandalwood oil components against a fungal disease called eumycetoma that causes serious skin infections, especially in tropical regions. They found that one component called (Z)-α-santalol was highly effective at killing the fungus and extending survival in laboratory-infected moth larvae, while actually being relatively safe. This natural compound shows promise as a potential new treatment for this neglected disease that currently relies on expensive drugs that are only 40% effective.

Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives

mycolabadmin

This review examines how doctors treat serious fungal infections and the growing problem of fungi becoming resistant to medications. The authors discuss different antifungal drugs, how they work, and why some fungi are becoming harder to treat. They emphasize that controlling fungal resistance requires coordinated efforts across hospitals, farms, and communities, especially since some agricultural pesticides are creating resistant strains that spread to sick patients.

From Mushrooms to Molecules: Exploring Depsidones in Ganoderma lucidum for Antioxidant and Anticancer Applications

mycolabadmin

This research examined reishi mushroom (Ganoderma lucidum), a traditional medicinal fungus, to find rare compounds called depsidones with potential cancer-fighting properties. Scientists extracted these compounds using different solvents and tested them against four types of cancer cells (liver, colon, breast, and lung cancer), finding that they successfully killed cancer cells while being safe to normal cells. Using advanced chemical analysis and computer modeling, they identified nine new depsidone compounds in reishi and showed how these compounds could bind to cancer-related proteins to stop tumor growth.

Past, present and future of antifungals: Advancements in mechanisms of action and resistance

mycolabadmin

Fungal infections are a growing global health problem, particularly for people with weakened immune systems, causing millions of deaths annually. Current antifungal medications are limited and increasingly ineffective due to drug-resistant fungi. This special issue explores new treatment strategies including novel drugs, combination therapies, and innovative approaches like nanoparticles and antimicrobial peptides to combat these serious infections.

New Positive TRPC6 Modulator Penetrates Blood–Brain Barrier, Eliminates Synaptic Deficiency and Restores Memory Deficit in 5xFAD Mice

mycolabadmin

Researchers developed a new drug candidate called C20 that activates TRPC6 proteins in the brain. In studies with Alzheimer’s disease mouse models, C20 protected nerve connections from damage, restored memory function, and successfully crossed the blood-brain barrier. The compound shows promise as a potential treatment for Alzheimer’s disease by strengthening the connections between brain cells that are damaged in the disease.

Investigation of the In Vitro Antioxidant, Anticholinesterase, Antiurease, Antityrosinase, and Cytotoxic Properties of a Novel Compound: 4-Methoxy-2-(4-Methoxyphenyl)Benzo[d][1,3,2]Dioxaborole

mycolabadmin

Scientists created a new chemical compound containing boron that showed promise as a potential medicine. The compound was effective at neutralizing harmful molecules in cells and inhibiting enzymes related to Alzheimer’s disease. Importantly, it did not damage healthy cells or kill cancer cells, suggesting it could be safe for future medical applications in treating various diseases.

Research Topic: drug development